F-1: Femto Technologies Files for Resale of 233 Million Common Shares Following Private Placement

Femto Technologies seeks to register the resale of up to 233 million common shares by selling shareholders after a recent $17 million private placement.

Summary

• Femto Technologies Inc. has filed a registration statement for the resale of up to 233,352,911 common shares.
• The shares are to be offered by selling shareholders, including those issuable upon exercise of warrants.
• The company will not receive any proceeds from the sale of these shares, but will receive the exercise price of any warrants that are exercised.
• The securities registered for resale represent almost 80 times the total number of common shares outstanding.
• The company completed a private placement on February 28, 2025, raising approximately $17 million through the sale of common shares and warrants.
• The company also entered into an exchange agreement with holders of old warrants to exchange them for new warrants.
• Femto Technologies is both an emerging growth company and a foreign private issuer, which allows for reduced public company reporting requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects such as the completion of certain developments and a recent capital raise, the significant losses, delays, and risks associated with the company's operations weigh heavily on the overall sentiment.

Positives

• The company has completed the development of its New CRM Platform and began generating revenues from it in 2023.
• The company has completed the development of its New Cannabis CRM Platform and is currently being tested at the Weizmann Institute of Science.
• The company has a contactless business license which will enable it to generate revenues without investing further in the Cannabis Farm.
• The company has a strong management team with experience in the technology and medical cannabis industries.

Negatives

• The company has incurred significant losses and may incur further losses in the development of its business.
• The company is dependent on a single client for the majority of its current revenues.
• The company faces risks inherent in an agricultural business, and an inability to grow crops successfully will interrupt our business activities.
• The company is subject to environmental, health and safety regulations and risks, which may subject us to liability under environmental laws.
• The company may not be able to obtain insurance coverage for all of the risks we face, exposing us to potential uninsured liabilities.
• The company is subject to changing regulations regarding corporate governance and public disclosure that have increased both our costs and the risk of non-compliance.

Risks

• The ongoing war between Israel and Hamas could disrupt the company's operations.
• The company's executive offices and research and development facilities are located in Israel.
• The company's timetables of various projects have been significantly delayed due to the war.
• The company decided to suspend the construction of the planned medical cannabis farm due to the proximity of the area designated for cultivation to the Gaza Strip.
• The company issued Enhanced Voting Preference Shares to its CEO, giving him substantial control over corporate actions.
• The company's Common Shares are subject to significant dilution due to the exercise of outstanding Warrants.
• The market price of the company's Subordinate Voting Shares may be volatile, which could result in substantial losses for investors.
• The company has never generated any revenue from product sales and this part of our business may never be profitable.
• The company's Sensera Device may contain errors or defects, which could result in damage to our reputation, lost revenues, diverted development resources and increased service costs, warranty claims and litigation.

Future Outlook

The company intends to focus on sales of the Sensera device and work to further pursue business opportunities in the world of FemTech. The Company intends to focus in the coming years on the development of additional products for the female wellness world, both at the level of technology and at the level of materials, some of which we expect will be CBD-based.

Industry Context

The document indicates a shift towards FemTech and women's wellness, aligning with growing market trends in personalized healthcare and technology-driven solutions for female health. The company's focus on CBD-based products also reflects the increasing interest in cannabis-derived treatments for various conditions.

Comparison to Industry Standards

• The company's shift towards FemTech aligns with the growth of companies like Elvie and Bloomlife, which focus on innovative products for women's health.
• The focus on CBD-based products is similar to companies like Charlotte's Web and CV Sciences, which are leaders in the CBD market.
• The company's CRM software business competes with established players like Salesforce and Microsoft Dynamics 365, requiring a strong value proposition to gain market share.

Related Party Transactions

• During the year ended December 31, 2023, the Company paid management and consulting fees in the amount of $1,874,710 to its Officers and Directors.
• As at December 31, 2023, $843 was owed from shareholders of the Company.
• As at December 31, 2023, $450,048 was owed to directors of the Company.

Stakeholder Impact

• Shareholders face potential dilution from the exercise of outstanding warrants.
• The company's ability to execute its business plan and generate returns for investors is subject to various risks, including the war in Israel and regulatory changes.
• The company's employees and consultants may be affected by the war in Israel and the company's decision to suspend the construction of the planned medical cannabis farm.

Next Steps

• The company needs to test the protype and commence manufacture of the Sensera product.
• The company intends to apply for an extension of one year and will be able to use the contactless license once the MCU approves the extention.
• The company intends to focus on sales of the Sensera device and work to further pursue business opportunities in the world of FemTech.
• The Company intends to focus in the coming years on the development of additional products for the female wellness world, both at the level of technology and at the level of materials, some of which we expect will be CBD-based.

Key Dates